CSS
AQST icon

Cubist Systematic Strategies’s Aquestive Therapeutics AQST Stock Holding History

Cubist Systematic Strategies’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44,076
Closed -$188K – 2945
2024
Q1 		$188K Buy
+44,076
New +$147K ﹤0.01% 3105
2023
Q3 		– Sell
-12,196
Closed -$20.1K – 3312
2023
Q2 		$20.1K Buy
+12,196
New +$22.1K ﹤0.01% 3180
2022
Q1 		– Sell
-29,926
Closed -$116K – 3543
2021
Q4 		$116K Buy
+29,926
New +$150K ﹤0.01% 3169
2020
Q4 		– Sell
-39,400
Closed -$191K – 2546
2020
Q3 		$191K Buy
+39,400
New +$258K ﹤0.01% 2143
2020
Q1 		– Sell
-17,926
Closed -$104K – 2150
2019
Q4 		$104K Buy
+17,926
New +$93.3K ﹤0.01% 2183
2018
Q4 		– Sell
-3,387
Closed -$59K – 2040
2018
Q3 		$59K Buy
+3,387
New +$55.8K ﹤0.01% 1686

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cubist Systematic Strategies's AQST Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Aquestive Therapeutics (AQST) in Q2 2024, closing a stake of 44,076 shares — an estimated $188K sold.

Cubist Systematic Strategies first reported a position in AQST in Q3 2018 and held it in 6 quarters. The position peaked at $191K in Q3 2020. 97 funds tracked by Wall St. Rank hold AQST as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Aquestive Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 44,076 Aquestive Therapeutics shares in Q2 2024, an estimated $188K.
  • Cubist Systematic Strategies first reported a position in Aquestive Therapeutics in Q3 2018 and held it in 6 quarters.
  • Cubist Systematic Strategies's Aquestive Therapeutics position peaked at $191K in Q3 2020.
  • 97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.